New insider activity at Zevra Therapeutics ( (ZVRA) ) has taken place on August 20, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director John B. Bode has made a significant investment in Zevra Therapeutics by purchasing 5,000 shares of the company’s stock. This transaction is valued at $45,800, reflecting a strong vote of confidence in the company’s future prospects.
Recent Updates on ZVRA stock
Zevra Therapeutics has recently experienced significant developments, including a strong financial performance in Q2 2025, driven by the successful U.S. launch of MIPLYFFA, which contributed to a 26% increase in net revenue. The company also bolstered its financial position by selling a Pediatric Rare Disease Priority Review Voucher for $150 million. However, challenges persist, such as the limited adoption of OLPRUVA, leading to a $58.7 million impairment charge on intangible assets. Despite these challenges, Zevra’s financial health remains robust with $217.7 million in cash and investments, supporting its strategic initiatives like European expansion and pipeline advancement. Analyst Jason Butler from Citizens JMP adjusted the price target due to these mixed results, highlighting the strong MIPLYFFA sales but also acknowledging the financial impairments and limited OLPRUVA adoption.
Spark’s Take on ZVRA Stock
According to Spark, TipRanks’ AI Analyst, ZVRA is a Neutral.
Zevra Therapeutics’ overall stock score is primarily influenced by its strong revenue growth and strategic financial maneuvers, as highlighted in the earnings call. However, the stock faces significant challenges, including negative profitability, bearish technical indicators, and cash flow difficulties. Addressing these issues will be crucial for improving its financial health and stock performance.
To see Spark’s full report on ZVRA stock, click here.
More about Zevra Therapeutics
YTD Price Performance: 2.80%
Average Trading Volume: 1,120,186
Technical Sentiment Signal: Hold
Current Market Cap: $516.4M